PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Low-Dose Aspirin Adjunct in Bipolar Depression: Promising Phase II Signal, Fragile Long-Term Data

acetylsalicylic acidaspirinlow-dose aspirinanti-inflammatory adjunctbipolar depressionbipolar disorderrandomised controlled trialphase IIrelapse preventionpsychopharmacologybleeding riskvalproate interaction Psychiatry / Psychopharmacology

Background Information

Could low-dose aspirin be a game-changer for bipolar depression?

Bipolar depression is challenging to manage, with few effective therapies available for acute and preventative treatment. ASA 150 mg/day improved depressive symptoms at 2 months (p = 0.005) and reduced relapse at 12 months (p = 0.026). While promising, this phase II study requires further validation in larger phase III trials before changing practice. Low-dose aspirin might aid in bipolar depression symptom relief and relapse prevention.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Dominiak M, Antosik AZ, Gędek A, Krawczyk-Syguda A, Biedrzycki S, Kuczyńska J, Dermanowski M, Mierzejewski P

Citation: Dominiak M, Antosik AZ, Gędek A, et al. Adjunctive Low-Dose Acetylsalicylic Acid in Bipolar Disorder: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase II Trial (ASPIRIN BD). Journal of clinical medicine. 2026;15(21). doi:10.3390/jcm15218349

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.